Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. - Wikidata - awgldk - TriplyDB

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

http://www.wikidata.org/entity/Q34792836

about

Tyrosine kinase - Role and significance in Cancer.Ten things you should know about protein kinases: IUPHAR Review 14 Structural Basis for Conformational Dynamics of GTP-bound Ras Protein Signalogs: orthology-based identification of novel signaling pathway components in three metazoans Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.Structural determinants of PERK inhibitor potency and selectivity Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin.Development and strategies of VEGFR-2/KDR inhibitors.Selectivity and potency of cyclin-dependent kinase inhibitors.Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib An integrative approach for the large-scale identification of human genome kinases regulating cancer metastasis Tyrosine kinase inhibitors: Multi-targeted or single-targeted?ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.Considerations for targeting malignant stem cells in leukemia.EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives Inhibitors of membranous adenylyl cyclases.Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma.Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.Normal and leukaemic stem cells.Second-generation kinase inhibitors.Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery?A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.Pathology of primary malignant bone and cartilage tumours.Protein kinases as targets for cancer treatment.(-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase Cell cycle kinases predicted from conserved biophysical properties Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.Protein kinase inhibitors: contributions from structure to clinical compounds.A survey of the population genetic variation in the human kinome.Evaluation of 6-chloro-N-[3,4-disubstituted-1,3-thiazol-2(3H)-ylidene]-1,3-benzothiazol-2-amine Using Drug Design Concept for Their Targeted Activity Against Colon Cancer Cell Lines HCT-116, HCT15, and HT29.Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis.Malignant glioma drug discovery - targeting protein kinases.The clonal evolution and therapeutic approaches of lung cancer.Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.Safety of available treatment options for renal cell carcinoma.

P2860

Q24791430-C7212C20-F522-452F-8BE1-24AB765F4600 Q26849417-B0E8D914-A317-4F1D-9147-6522D82E64C3 Q27661719-EB9D637D-A989-4ADC-9878-5AA94FE881C3 Q28478034-D3237002-82F3-451B-85EF-0E88E395042F Q33691544-36501817-7C1E-4A8F-9251-46DD3AB38917 Q33744382-79D8A65F-BAF7-46AD-9EA4-F74429A87F1A Q33749036-A79456FE-D451-4BFF-94A0-CD4635A55BA9 Q33770326-73D562AE-83C3-4B57-9072-E23C5FB54E34 Q33872751-F3AB526B-3C1E-43A1-B0CA-5DEA4CC4EDEE Q34338431-2B940C37-F1D5-4809-B7DD-88810B94A46D Q34436101-6BAE4DA1-D648-4418-B79B-F2C1A01CD3E3 Q34651981-3B2D8B41-5637-4D76-87B8-A04263063335 Q34705820-288D77EA-E25C-4869-8DE6-5F73A342EE63 Q34764556-EBB022B8-77AE-4D89-8340-4267E4218DB0 Q34983846-3287E37D-4144-4A06-8852-6EE134F6323A Q35171274-1A5A049A-A060-4E15-8D26-D7DDAD9C042B Q35609713-FB4BD8F3-409E-4677-A4D4-48EBEB3ECD94 Q35692619-F4F178CA-D16E-4FC7-870C-3845C6570D6A Q35729147-E70F85AE-6AAE-49E7-9B8B-382D7AF79EC4 Q35740305-CF8F9304-A151-423A-92A2-548EA45D2FB4 Q35747269-CD8100BD-0590-488B-80E8-206A2F95E837 Q36083906-38121AAF-661C-41FF-B988-FDF9C2478FBC Q36158713-93AFC88B-A457-4026-8EB8-1276C979651A Q36228053-41826B35-EB35-4319-982C-3B9DAD434714 Q36268315-0363CDA8-62F7-49C6-B8BF-46CD323B1F52 Q36381266-F8766FB5-2779-48FE-B610-E92D2AE9C820 Q36511074-7623C3F0-F77E-4FCD-ABCC-FE74F0B0FAB3 Q36582268-E78891C7-AC01-4DA8-B041-69855449EF4B Q36918131-FAB253DA-6CF9-4887-AC30-945B389585A7 Q36940412-F83E9903-B508-49DE-9B64-60B30C6C88FF Q37069889-CA3DF461-C253-4CE3-8B35-00F2751ACE96 Q37406648-85764034-ABC3-4E12-92DF-33FFB5B4992B Q37417742-DFDE81D7-2329-4884-8609-FA27C8A81D70 Q37419761-B201EDC4-7523-4471-A16D-6F4F3C7D3417 Q37698346-4BF52FA6-EB8B-4C0A-8D66-AF21ED6E0E99 Q38078271-608DF830-5111-47CB-85DC-5A56968A417E Q38089834-FC1FB2DF-6E39-4FD2-9355-4C7835356776 Q38196755-F28A43FA-35BD-496F-A6A5-7545D126C829 Q38342295-EA8AB63C-6378-4C7F-AA3E-3CF374866A45 Q38824719-E174F56B-5B96-492F-96B2-AE3A959E00FF

P2860

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

http://www.wikidata.org/entity/Q34792836

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@ast

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@en

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@nl

type

label

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@ast

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@en

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@nl

prefLabel

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@ast

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@en

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@nl

P1433

Q34792836-6EEAD876-20C9-46B7-97DA-3377AFD0D551

P1476

Q34792836-4F4BEBD5-2A30-4DD8-B2B1-EF7491563A1C

P2093

Q34792836-0FE92605-A992-4F16-9315-8186FF5D82AB

Q34792836-2D6FE46E-61AF-436F-93FB-592F502AE9D4

Q34792836-4ABDC722-741B-4C1D-939A-660F9A94CE94

Q34792836-699D36EB-D21D-437E-B7EE-3840FBAD56D7

Q34792836-6E54CB6E-7374-4FE9-A924-3F60225E4EF8

Q34792836-75FE3515-3A62-42EC-9974-91825BBC252E

Q34792836-7B557C7E-CA45-4E96-8975-0A8C698764CB

Q34792836-86169ED4-D722-4F56-B994-AC3DDA57D7DE

Q34792836-A734BF7E-DD24-4AAB-B5E9-60A07BA5E9CC

Q34792836-C35A2517-A0C4-48A8-B881-BA5B9AF5790F

P304

Q34792836-59827CB4-5893-4BEF-92A7-8E848C9DAB1D

P31

Q34792836-53A21C15-387B-4DE9-86BA-AC1E5B898535

P356

Q34792836-371F0604-2AC2-473A-9C56-0927CE929FA4

P433

Q34792836-AE9563AB-930B-47B6-A9A7-12357F15BC80

P478

Q34792836-C19A9E8B-D11F-4F44-8B0E-CDE2ED6A96CE

P577

Q34792836-2AFE63D4-C74C-4BD7-9E48-C3BACEA030E5

P698

Q34792836-0D0D7142-0937-4C38-8B13-0DB58E2B16BB

P356

S0163-7258(02)00179-1

P1433

Pharmacology & Therapeutics

P1476

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

@en

P2093

Bhabatosh Chaudhuri

http://www.w3.org/2001/XMLSchema#string

Doriano Fabbro

http://www.w3.org/2001/XMLSchema#string

Elisabeth Buchdunger

http://www.w3.org/2001/XMLSchema#string

Gabriele Fendrich

http://www.w3.org/2001/XMLSchema#string

Giorgio Caravatti

http://www.w3.org/2001/XMLSchema#string

Heinz Fretz

http://www.w3.org/2001/XMLSchema#string

Janis Liebetanz

http://www.w3.org/2001/XMLSchema#string

Jürg Zimmermann

http://www.w3.org/2001/XMLSchema#string

Jürgen Mestan

http://www.w3.org/2001/XMLSchema#string

Pascal Furet

http://www.w3.org/2001/XMLSchema#string

P304

79-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0163-7258(02)00179-1

http://www.w3.org/2001/XMLSchema#string

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12191602

http://www.w3.org/2001/XMLSchema#string